ClinicalTrials.gg
CompletedNCT04498741Updated Oct 13, 2021

Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects

A Phase 1 interventional study of EDP-938 and EDP-938 in RSV Infection, sponsored by Enanta Pharmaceuticals, Inc. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-10-13.

Sponsored by Enanta Pharmaceuticals, Inc · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was May 2021, 5 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
89
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing EDP-938 in Respiratory Syncytial Virus Infections — 1 open to participants now, 1 under way, none of them phase 3. EDP-938 · Respiratory Syncytial Virus Infections.

Enrollment
5th of 10
89 · median 81
Started
2020
the only one that year
Phase 1
6 of 10
none open now
Registered
5th of 10
by date
Lead sponsor
10 of 10
Enanta Pharmaceuticals, Inc

Among the 10 studies testing EDP-938 in Respiratory Syncytial Virus Infections, this one is the 5th largest by enrollment, is the only one that started in 2020, is one of 6 in phase 1, and was the 5th registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

1 of the 10 studies testing EDP-938 in Respiratory Syncytial Virus Infections is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About EDP-938

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing EDP-938 in Respiratory Syncytial Virus Infections, or all of them as a file.
02

Study summary

A Non-Randomized, Open-Label, Three-Part, Drug-Drug Interaction Study to Evaluate the Effects of tacrolimus, dabigatran, rosuvastatin and midazolam on the Pharmacokinetics and Safety of EDP-938 in Healthy Subjects

03

Conditions studied

  • RSV Infection

Keywords

  • drug-drug interaction
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • An document signed and dated by the subject.
  • Healthy male and female subjects of any ethnic origin between the ages of 18 and 55 years, inclusive.
  • Screening (BMI) of 18 to 30 kg/m2 with a minimum body weight of 50 kg
  • Female subjects of must agree to use two effective methods of from the date of Screening until 90 days after the last dose of EDP 938.

Exclusion criteria

Exclusion Criteria:

  • evidence or history of illness or disease
  • Pregnant or nursing females.
  • History of febrile illness within 7 days prior to the first dose of study drug or subjects with evidence of active infection.
  • A positive urine drug screen at Screening or Day -1.
  • Current tobacco smokers or use of tobacco within 3 months prior to Screening.
  • Any condition possibly affecting drug absorption (e.g., gastrectomy, cholecystectomy).
  • History of regular alcohol consumption.
  • Participation in a clinical trial within 30 days prior to the first dose of study drug.
  • For Part 1 subjects:
  • Clinical history or evidence at Screening consistent with hyperkalemia, hypertension and/or diabetes mellitus
  • For Part 2 Subjects:
  • Clinical history or evidence at screening of medically significant bleeding
  • History of a mechanical heart valve placement, a thromboembolic event or clinically significant thrombotic event, an disease, eg, systemic lupus erythematosus (SLE), or recurrent spontaneous abortions
  • A count \<LLN, or >, or aPTT > ULN at Screening
  • Ongoing daily use of nonsteroidal anti-inflammatory drugs
  • For Part 3 subjects:
  • and/or ALT >ULN at Screening
  • For Part 4 subjects:
  • History of glaucoma
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
89 participants (actual)

Study arms

  • Experimental
    EDP-938 and tacrolimus interaction (Part 1)

    Drug: EDP-938 · Drug: Tacrolimus

  • Experimental
    EDP-938 and dabigatran interaction (Part 2)

    Drug: EDP-938 · Drug: Dabigatran

  • Experimental
    EDP-938 and rosuvastatin interaction (Part 3)

    Drug: EDP-938 · Drug: Rosuvastatin

  • Experimental
    EDP-938 and midazolam interaction (Part 4)

    Drug: EDP-938 · Drug: Midazolam

Interventions

  • Subjects will receive EDP-938 once daily on Days 10 through 27 (Part 1)

  • Subjects will receive EDP-938 once daily on Days 5 through 15 (Part 2)

  • Subjects will receive EDP-938 once daily on Days 5 through 15 (Part 3)

  • Subjects will receive tacrolimus once daily on Day 1 and Day 24

  • Subjects will receive dabigatran once daily on Day 1 and Day 13

  • Subjects will receive rosuvastatin once daily on Day 1 and Day 13

  • Subjects will receive EDP-938 once daily on Days 3 through 16 (Part 4)

  • Subjects will receive midazolam once daily on Day 1 and Day 16

06

What researchers measure

Primary outcomes

  1. Cmax of tacrolimus with and without coadministration with EDP-938

    Time frame: up to 29 days

  2. AUC of tacrolimus with and without coadministration with EDP-938

    Time frame: up to 29 days

  3. Cmax of dabigatran with and without coadministration with EDP-938

    Time frame: up to 17 days

  4. AUC of dabigatran with and without coadministration with EDP-938

    Time frame: up to 17 days

  5. Cmax of rosuvastatin with and without coadministration with EDP-938

    Time frame: up to 17 days

  6. AUC of rosuvastatin with and without coadministration with EDP-938

    Time frame: up to 17 days

  7. Cmax of midazolam with and without coadministration with EDP-938

    Time frame: up to 17 days

  8. AUC of midazolam with and without coadministration with EDP-938

    Time frame: up to 17 days

Secondary outcomes

  1. Safety measured by adverse events

    Time frame: up to 34 days

07

Study locations

1 site
  • Pharmaceutical Research Associates, Inc.,
    Lenexa, Kansas 66219, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in May 2021, 10 months.

Of 44 industry-sponsored phase 1 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 10 months is above that.

Counting every sponsor, half of 57 studies reached it within 8 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2020
First posted
Aug 4, 2020
StartActual
Jul 8, 2020
Primary completionActual
May 27, 2021
CompletionActual
Jun 1, 2021
Last update
Oct 13, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 13, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04498741
Collaborators
Pharmaceutical Research Associates
Responsible party
Sponsor
First posted
Aug 4, 2020
Start date
Jul 8, 2020
Primary completion
May 27, 2021
Completion
Jun 1, 2021
Last update
Oct 13, 2021

Study contacts

Enanta Pharmaceuticals, Inc
study director · Enanta Pharmaceuticals, Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: EDP-938 · Tacrolimus · Dabigatran

Start the discussion